National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
Responding to the American Association of Justice’s “Unequal Harm: The Disproportionate Damage to Women From Dangerous Drugs and Medical Device”
LOS ANGELES (PRWEB) August 02, 2013
Baron and Budd, a national law firm, is confronting the alleged association between type 2 diabetes and Lipitor use in female patients by delving into Lipitor lawsuit investigations. A popular cholesterol-lowering drug used to lower LDL, or “bad” cholesterol, and triglycerides, Lipitor has not been recalled. However, the Food and Drug Administration (FDA) has asked that the manufacturer of Lipitor, Pfizer, cite the risk of increased blood sugar on the drug’s warning label. This request follows the publication of several studies that allege a connection between Lipitor use and the development of type 2 diabetes in women. (http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm)
In May of 2013, the American Association of Justice (AAJ) published an article titled Unequal Harm: The Disproportionate Damage to Women from Dangerous Drugs and Medical Devices that helps to expose the heightened susceptibility some women may have to dangerous drugs. The article cites many reasons. Women are sometimes left out of drug and product safety inspections and testing. Also different hormones and body compositions can make women more susceptible, or cause them to react differently, to medications tested previously on men. (http://www.justice.org/cps/rde/xchg/justice/hs.xsl/20936.htm)
“We are concerned about the alleged risk of developing type 2 diabetes for women taking Lipitor. Our office is dedicated to helping those who have been harmed by neglect, including dangerous drugs and we will work to make sure that this serious alleged risk is addressed,” said Russell Budd of Baron and Budd.
In addition to Lipitor, several other dangerous drugs have recently come into question for their alleged propensity to harm women.
Women who may have developed type 2 diabetes while taking Lipitor are asked to contact Baron and Budd immediately at 1.866.844.4556 for a free consultation to find out if they are eligible to participate in a Lipitor lawsuit. Currently, the Lipitor lawsuit involves women who developed type 2 diabetes while taking Lipitor.
Baron and Budd has been Protecting What’s Right for more than 35 years. From asbestos cancer to water contamination, the Gulf oil spill, financial fraud, deceptive advertising and dangerous drugs, Baron and Budd has established a national reputation as one of the leading plaintiffs’ law firms in the country. Baron and Budd has been selected eight times to the National Law Journal’s esteemed Plaintiffs’ “Hot List” as an exemplary law firm. Most recently, Baron and Budd was chosen as a finalist for the Public Justice 2013 Trial Lawyer of the Year Award for its work on the atrazine contamination lawsuit. This is the fourth time in the past six years that Baron and Budd attorneys have been chosen as finalists for the Trial Lawyer of the Year Award.
In addition to Lipitor lawsuits, Baron & Budd is handling Transvaginal Mesh lawsuits, Granuflo lawsuits and Actos lawsuits. To learn more or to see if you might have a case, call Baron and Budd at 1.866.844.4556 or visit the firm’s website at http://baronandbudd.com/areas-of-practice/pharmaceuticals/lipitor-lawsuit/.
About Baron & Budd
With offices in Dallas, Austin, Baton Rouge and Los Angeles, Baron and Budd is a nationally recognized law firm with more than 35 years of experience “Protecting What’s Right” for people, businesses and communities harmed by negligence corporations and practices. Because of Baron and Budd’s size and resources, the law firm is capable of handling large and complex cases. Baron and Budd represents both individuals and governmental and business entities in areas as diverse as mesothelioma caused by asbestos exposure, deceptive advertising, harmful drugs, medical devices, FLSA violations, toxic exposure, the Gulf oil spill, consumer financial fraud and water contamination.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/8/prweb10984105.htm